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Introduction
In the past, pain mechanisms in osteoarthritis (OA) have
received surprisingly little attention, although this is now
changing. Attempts to discriminate between OA and other
rheumatologic disorders, such as rheumatoid arthritis,
through verbal descriptions of pain have generally proved
unsuccessful as the patterns of pain often overlap. Use-
related pain in OA is common but rest pain and night pain
sometimes occur, and a variety of patterns of pain are
described by different patients, varying from a dull ache to
sharp, stabbing pains [1]. It seems probable that a variety of
different mechanisms contribute to symptoms in this disorder
and that the relative importance varies among individuals.
The presence and severity of joint pain correlate poorly
with structural evidence of joint damage. Current evidence
suggests that OA joint damage predisposes to pain, but that
little correlation between pain severity and the extent of
joint damage exists. The probable explanation of these
observations lies in that fact that pain perception arises in
response to a complex series of underlying neurophysio-
logic events involving transduction of stimuli, transmission
of encoded information, and subsequent modulation of this
activity at both peripheral and more central levels. In all but
acute situations, the relation between tissue injury and
resultant symptoms becomes less well deﬁned and more
susceptible to extraneous inﬂuences originating both within
and external to the individual.
Minor injuries or damage within the joint produce short
lived excitation of specialized high threshold nociceptors
with brief, spatially localized pain. More severe tissue
damage associated with the release of inﬂammatory
mediators produces not only direct nociceptor excitation,
but also modiﬁed response properties to subsequent stimuli
(peripheral sensitization) [2]. Under these circumstances,
the response to a noxious stimulus becomes exaggerated.
Alternatively, normally innocuous stimuli such as standing
or walking may produce pain.
Pathophysiology of Joint Pain
Mammalian synovial joints are richly supplied with sensory
nerve ﬁbers, the terminals of which express multiple
receptors that characteristically become active across rela-
tively narrow ranges of stimulus intensity. The sensitivity of
these receptors is governed by a critical interaction with the
local microenvironment as well as by factors related to
previous stimuli. The cellular mechanisms by which these
changes occur involve early post-translational changes to
receptor ion channels and later, longer lasting transcription-
dependent mechanisms involving changes to the chemical
phenotype of the cell [3] (Fig. 1).
Parallel changes to those observed in the periphery
occur at more central levels (central sensitization) (Fig. 2).
At a spinal level, this involves exaggerated responses to
normal stimuli together with expansion of receptive ﬁeld
size producing tenderness and referred pain in areas away
from the site of injury [4]. Functional imaging studies of the
brain following noxious stimuli using fMRI and PET show
a complex pattern with discrete areas of activity throughout
both cerebral hemispheres [5]. The consequences of cortical
sensitization remain unclear, but may produce the state of
hypervigilance and other more general phenomenon ob-
served in patients with chronic pain.
Mediators of Pain in OA
Several lines of evidence point to the importance of
mediators released from either synovium or bone as being
important to symptoms in OA. The presence of knee pain
has been shown to correlate with MRI ﬁndings of moderate
or larger effusions as well as synovial thickening [6]. Bone
marrow lesions detected on MRI are more prevalent in
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individuals with OA who have knee pain than in those who
are symptom-free [4]. Changes in bone marrow lesions and
synovitis are associated with ﬂuctuations in knee pain in
patients with knee OA, and pain resolution occurs more
frequently when bone marrow lesions become smaller [14].
Potential peripheral targets to control OA pain currently
under investigation include inﬂammatory mediators and
their key receptors such as prostanoids, kinins, cytokines,
and chemokines; sodium and calcium ion channels; and
growth factors [9]. An example of the latter is nerve growth
factor (NGF), which is produced by various cell types
including ﬁbroblasts, keratinocytes, Schwann cells, and a
range of immune cells. Acting via neuronal trkA receptors,
NGF sensitizes articular pain ﬁbers and changes pain
thresholds [10]. Blocking activity of NGF with a neutral-
izing humanized monoclonal antibody (tanezumab) has
been shown to reduce OA knee pain [11]. However,
accelerated joint damage with radiographic evidence of
bone necrosis resulting in knee replacement has been
reported in some patients, resulting in the FDA putting
clinical trials with this compound on hold. Reasons for the
accelerated damage remain unclear, but the episode raises
enormously important issues for the development of future
analgesics for OA. One explanation given has been that the
absence of joint pain led to excessive wear; however, other
possibilities include a cross-reaction between tanzemab and
other (vascular) receptors or an as yet unidentiﬁed trophic
role for NGF in maintenance of joint homeostasis.
Psychophysical studies of patients with symptomatic OA
have reported diffuse alteration of pain perception in response
to various stimuli [12] with subjects having increased pain
intensity and signiﬁcantly larger referred and radiating pain
areas than matched controls. Local changes to nociceptive
activity are highly unlikely to account for these ﬁndings and
point to the presence of enhanced central pain processing in
OA. Consistent with this, studies that have combined
psychophysical methods with functional brain imaging have
Fig. 1. Peripheral sensitization. Contribution of peripheral nocicep-
tors to pain. a Acute pain: Noxious stimuli activate high threshold ion
channels with resultant propagation of axon potentials. b Early phase
sensitization: Mediators, including prostaglandin E2, activate kinases
to phosphorylate receptors/ion channels and lower threshold for
activation. c Late phase sensitization: Gene induction in response to
growth factors resulting in changes to cell phenotype. Adapted from
[16]. Adapted with permission of John Wiley & Sons, Inc.
Fig. 2. Central sensitization. Contribution of spinal cord neurones to
pain. a Acute pain: Activation of AMPA receptor by glutamate.
NMDA receptor blocked. b Early phase sensitization: Activation of
NMDA receptor following removal of magnesium ion block [medi-
ated by substance P (SP) acting on NK1 receptors—black spheres and
triangle, respectively]. c Late phase sensitization: Gene induction with
enhanced production of prostaglandins and other local mediators.
Modulation by descending facilitatory/inhibitory pathways. Adapted
from [16]. Adapted with permission of John Wiley & Sons, Inc.
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reported increased activation in the brainstem of OA patients
following punctuate stimulation compared to controls [13].
OA pain has also shown to be associated with increased
activity in areas concerned with the processing of fear and
emotions and in averse conditioning, including the cingulate
cortex, the thalamus, and the amygdala [14]. This is in accord
with other studies showing an important relationship between
psychosocial factors and pain reporting in OA, particularly
anxiety, depression, catastrophizing, coping strategies, and
social isolation [15].
Conclusions
It seems likely that OA pain reﬂects a state of altered pain
processing such that everyday stimuli are perceived as being
painful. These changes arise in response to a critical
interaction with particular joint, bone, and periarticular factors
that may well vary among individuals. The resultant sensiti-
zation of nociceptive pathways at both peripheral and central
levels is then dependent on constitutional factors unique to an
individual—such as gender, age, and previous history, as well
as environmental factors including culture and lifestyle.
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